[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S, Evdokiou A: Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer; 2003 Jul 7;89(1):206-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.
  • We observed that recombinant Apo2L/TRAIL was proapoptotic in early-passage BTK-143 osteogenic sarcoma cells, inducing 80% cell death during a 24 h treatment period.
  • Importantly, treatment of resistant cells with the chemotherapeutic agents doxorubicin, cisplatin and etoposide reversed the resistance to Apo2L/TRAIL, which was associated with drug-induced upregulation of mRNA encoding the death receptors DR4 and DR5.
  • BTK-143 cells thus represent a useful model system to investigate both the mechanisms of acquisition of resistance of tumour cells to Apo2L/TRAIL and the use of conventional drugs and novel agents to overcome resistance to Apo2L/TRAIL.
  • [MeSH-major] Apoptosis / drug effects. Gene Expression Regulation, Neoplastic. Membrane Glycoproteins / pharmacology. Osteosarcoma / pathology. Tumor Necrosis Factor-alpha / pharmacology
  • [MeSH-minor] Antigens, CD95. Apoptosis Regulatory Proteins. Drug Resistance, Neoplasm. Humans. Ligands. TNF-Related Apoptosis-Inducing Ligand. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Jan;20(1):205-12 [10594023.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(3):199-206 [10663637.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):847-53 [10706092.001]
  • [Cites] J Immunol. 2000 Apr 15;164(8):3961-70 [10754286.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):330-6 [10888418.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):23319-25 [10770955.001]
  • [Cites] Hepatology. 2000 Sep;32(3):482-90 [10960439.001]
  • [Cites] FEBS Lett. 2000 Oct 6;482(3):193-9 [11024459.001]
  • [Cites] J Exp Med. 2000 Oct 16;192(8):F21-5 [11034612.001]
  • [Cites] J Urol. 2001 Jan;165(1):263-70 [11125422.001]
  • [Cites] Cell Death Differ. 2000 Nov;7(11):1127-36 [11139287.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1645-51 [11245478.001]
  • [Cites] Curr Biol. 2001 Feb 20;11(4):273-6 [11250157.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):10767-74 [11278284.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):409-16 [11283615.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):966s-973s [11300498.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2122-33 [11360196.001]
  • [Cites] J Biol Chem. 2001 Aug 31;276(35):32585-90 [11384965.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1572-81 [11587215.001]
  • [Cites] FEBS Lett. 2002 Jan 2;510(1-2):37-40 [11755527.001]
  • [Cites] Int J Cancer. 2002 Jun 1;99(4):491-504 [11992538.001]
  • [Cites] Bone. 2002 Oct;31(4):448-56 [12398939.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Science. 1997 Apr 4;276(5309):111-3 [9082980.001]
  • [Cites] Science. 1997 Aug 8;277(5327):815-8 [9242610.001]
  • [Cites] Science. 1997 Aug 8;277(5327):818-21 [9242611.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3697-707 [9288776.001]
  • [Cites] EMBO J. 1997 Sep 1;16(17):5386-97 [9311998.001]
  • [Cites] J Exp Med. 1997 Oct 6;186(7):1165-70 [9314565.001]
  • [Cites] Curr Biol. 1997 Dec 1;7(12):1003-6 [9382840.001]
  • [Cites] Immunity. 1997 Dec;7(6):813-20 [9430226.001]
  • [Cites] Immunity. 1997 Dec;7(6):821-30 [9430227.001]
  • [Cites] FEBS Lett. 1998 Mar 6;424(1-2):41-5 [9537512.001]
  • [Cites] J Biol Chem. 1998 Jun 5;273(23):14363-7 [9603945.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] J Immunol. 1998 Sep 15;161(6):2833-40 [9743343.001]
  • [Cites] Nat Med. 1999 Feb;5(2):157-63 [9930862.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):734-41 [9973225.001]
  • [Cites] J Leukoc Biol. 1999 May;65(5):535-42 [10331480.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6153-8 [10626806.001]
  • (PMID = 12838325.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Apoptosis Regulatory Proteins; 0 / Ligands; 0 / Membrane Glycoproteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC2394221
  •  go-up   go-down


2. Han LY, Ye MZ, Li HL, Wang BW, Wang Q: [Retention of biological features in human placental mesenchymal stem cells transfected by multidrug resistance gene]. Zhonghua Yi Xue Za Zhi; 2009 Oct 27;89(39):2793-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean cumulative time of population doubling was 23.9 hours.
  • Furthermore these transfected cells demonstrated osteogenic and adipogenic differentiation potentials under appropriate conditions.
  • It might provide experimental references for the application of P-MSCs in high-dose tumor chemotherapy.
  • [MeSH-major] Drug Resistance, Multiple / genetics. Mesenchymal Stromal Cells / cytology. P-Glycoprotein / genetics. Placenta / cytology. Transfection
  • [MeSH-minor] Cell Differentiation. Drug Resistance, Neoplasm / genetics. Female. Gene Transfer Techniques. Genetic Vectors. Humans. Pregnancy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137607.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / P-Glycoprotein
  •  go-up   go-down


3. Valentí V, López-Pousa A, Gonzalez Y, Farré N: Radiation-induced mandibular osteogenic sarcoma: report of a case and review of the literature. J Craniofac Surg; 2005 May;16(3):452-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced mandibular osteogenic sarcoma: report of a case and review of the literature.
  • The case of a 56-year-old man with osteogenic sarcoma of the mandible diagnosed 7 years after radiotherapy treatment of a laryngeal cancer is reported.
  • Surgery was the initial treatment.
  • The progress was poor after local and pulmonary relapse, without response to chemotherapy treatment.
  • The authors have found in the literature 30 cases of mandibular radiation-induced osteogenic sarcomas, most of them secondary to treatment of benign lesions, none of them secondary to treatment of a laryngeal cancer, as was seen in their case.
  • [MeSH-minor] Brain Neoplasms / secondary. Carcinoma, Squamous Cell / radiotherapy. Fatal Outcome. Humans. Laryngeal Neoplasms / radiotherapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915114.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. McGrath BE, Schlatterer D, Mindell ER: Case reports: Osteogenic sarcoma of the patella spread to lateral meniscus after arthroscopy. Clin Orthop Relat Res; 2006 Mar;444:250-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case reports: Osteogenic sarcoma of the patella spread to lateral meniscus after arthroscopy.
  • Our patient presented with a rare lesion, a patella osteogenic sarcoma that spread to the anterior horn of the lateral meniscus via the arthroscope.
  • The specimen was diagnosed as an osteogenic sarcoma.
  • After 2 weeks of neoadjuvant chemo-therapy, the patient refused additional chemotherapy.
  • Pathologic examination of the resected specimen showed osteogenic sarcoma of the patella and a completely separate 1.0-cm nodule of osteogenic sarcoma tissue growing in the anterior horn of the lateral meniscus.
  • [MeSH-major] Arthroscopy / adverse effects. Bone Neoplasms / pathology. Menisci, Tibial. Neoplasm Seeding. Osteosarcoma / secondary. Patella. Soft Tissue Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446587.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Yoshida A, Edgar MA, Garcia J, Meyers PA, Morris CD, Panicek DM: Primary desmoplastic small round cell tumor of the femur. Skeletal Radiol; 2008 Sep;37(9):857-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary desmoplastic small round cell tumor of the femur.
  • Desmoplastic small round cell tumor (DSRCT) is a rare malignant neoplasm typically involving the abdominal cavity of a young male.
  • Extra-abdominal occurrence of this tumor is very rare.
  • The patient presented with knee pain, and radiological findings were strongly suggestive of osteogenic sarcoma.
  • Despite chemotherapy and complete tumor excision, the patient developed progressive lung and bone metastases and died 3 years after initial presentation.

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3028-36 [9738572.001]
  • [Cites] Hum Pathol. 2000 May;31(5):532-8 [10836292.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):823-35 [12131150.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1408-13 [10555010.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):454-9 [17325488.001]
  • [Cites] Pediatr Pathol. 1989;9(2):177-83 [2473463.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23 (2):159-65 [9989842.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 15;156(2):167-71 [15642398.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2837-40 [8187063.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):499-513 [1709557.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3423-30 [12972518.001]
  • (PMID = 18470511.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Patel SG, Meyers P, Huvos AG, Wolden S, Singh B, Shaha AR, Boyle JO, Pfister D, Shah JP, Kraus DH: Improved outcomes in patients with osteogenic sarcoma of the head and neck. Cancer; 2002 Oct 1;95(7):1495-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcomes in patients with osteogenic sarcoma of the head and neck.
  • BACKGROUND: The current study reviews the authors' recent institutional experience in the treatment of osteosarcoma of the head and neck (OSHN).
  • Surgery was employed in all 44 patients, neoadjuvant chemotherapy was administered in 30 patients (68%), and postoperative radiation therapy was given to 7 patients (16%).
  • Histologic response was "unfavorable" in 22 of 30 patients (73%) who were treated with neoadjuvant chemotherapy.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10849
  • (PMID = 12237918.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Benjamin R, Helman L, Meyers P, Reaman G: A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung. Hum Gene Ther; 2001 Aug 10;12(12):1591-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteosarcomas are malignant tumors arising from skeletal tissue and occur most frequently during childhood and adolescence.
  • Chemotherapy, better surgical techniques, and improved staging methods now allow most patients to be treated with limb-sparing surgery and to be cured of their disease.
  • The lung is the most frequent metastatic site and is treated with chemotherapy and surgical resections.
  • Multiple resections for repeated recurrences that are limited to the lung are not uncommon but are limited by the amount of lung tissue that can be removed and become futile as recurrences become more frequent.
  • Although a main component of initial therapy, chemotherapy has not been shown to be of benefit for recurrent disease.
  • Direct introduction of therapeutic genes into malignant cells in vivo may provide effective treatment of solid tumors.
  • The proposed study will use the adenoviral vector Ad-OC-E1a (OCaP1), which contains a murine osteocalcin (OC) promoter to regulate the production of the adenoviral E1a protein to allow for restricted viral replication and subsequent lysis of tumor cells.
  • It functions primarily in osteoblasts found in growing bone and is highly expressed in osteogenic sarcomas.
  • Because adenovirus is quickly cleared by normal tissues, especially the liver, systemic administration has been problematic.
  • Although bioavailability would be decreased following exposure to the liver, the OcaP1 construct should not be hepatotoxic due to OC-restricted tissue expression of the Ela protein.
  • Metastatic disease to the lung is a major problem and often is the cause of death for patients with osteogenic sarcoma.
  • Treatment of pulmonary metastases could potentially be accomplished using intravenously administered OcaP1 since the material would pass through the lung prior to reaching the systemic circulation.
  • This protocol is a phase I/II investigational study of bolus intravenous injections of Ad-OC-E1a for the treatment of chemotherapy-refractory osteogenic sarcoma that has metastasized to the lungs.
  • After safety has been established in the first part of the trial, we will evaluate the anti-tumor activity of OCaP1.
  • Because the matrix associated with osteogenic sarcoma may not change despite tumor necrosis, radiographic evaluation alone has not been considered sufficient to evaluate response in this disease.
  • Histologic criteria that assess the amount of necrosis have been shown to have prognostic significance and are a key component of the anti-tumor response assessment.
  • Therefore, the anti-tumor assessments will be carried out in patients for whom resection of their pulmonary metastases is clinically indicated.
  • Responses will be graded using radiographic and histologic objective response criteria that are considered standard for osteogenic sarcoma.
  • A total of 14 to 25 patients, depending upon whether objective anti-tumor responses occur, will be studied in this part of the protocol.
  • [MeSH-major] Adenoviridae / genetics. Bone Neoplasms / therapy. Clinical Protocols. Gene Transfer Techniques. Osteosarcoma / therapy
  • [MeSH-minor] Cell Line. Culture Media, Serum-Free / pharmacology. Dose-Response Relationship, Drug. Genetic Therapy / adverse effects. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Lung Neoplasms / therapy. Maximum Tolerated Dose. Neoplasm Metastasis. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11529247.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free
  •  go-up   go-down


8. Eyesan SU, Obalum DC, Onovo DO, Ketiku KK, Abdulkareem FB: Indications for ablative surgery in extremity musculoskeletal tumours. Nig Q J Hosp Med; 2009 Sep-Dec;19(4):206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Surgical options for treatment of extremity musculoskeletal tumours include excision [limb sparing] surgery or amputation [limb ablation].
  • Data such as age, gender, presenting complaints, anatomic location of the tumour, clinical stage, type of ablative surgery and adjuvant treatment offered, histologic type of tumour, and treatment outcome were documented.
  • RESULTS: Nineteen patients had ablative surgery as a mode of treatment.
  • Seven patients [6 males and 1 female] refused ablative surgery and voluntarily discontinued treatment.
  • Most tumours were located in the lower limb and all patients that had ablative treatment presented with stage 3 or 4 disease.
  • Osteogenic sarcoma was the most common diagnosis, accounting for 4 cases [21.1%].
  • Adjuvant chemotherapy was prescribed for all patients.
  • [MeSH-major] Amputation / methods. Bone Neoplasms / surgery. Lower Extremity / surgery. Neoplasms, Bone Tissue / surgery. Upper Extremity / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Hospitals, Special. Humans. Male. Middle Aged. Neoplasm Staging. Nigeria. Orthopedics. Prospective Studies. Radiotherapy, Adjuvant. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20836332.001).
  • [ISSN] 0189-2657
  • [Journal-full-title] Nigerian quarterly journal of hospital medicine
  • [ISO-abbreviation] Nig Q J Hosp Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


9. Penel N, Van Haverbeke C, Lartigau E, Vilain MO, Ton Van J, Mallet Y, Lefebvre JL: Head and neck soft tissue sarcomas of adult: prognostic value of surgery in multimodal therapeutic approach. Oral Oncol; 2004 Oct;40(9):890-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck soft tissue sarcomas of adult: prognostic value of surgery in multimodal therapeutic approach.
  • Adult head and neck soft tissue sarcomas (AHNSTS) are rare, and data concerning treatment results are spare.
  • Aggressive fibromatosis, dermatofibrosarcoma, Kaposi sarcoma, chondrosarcoma and osteogenic sarcoma were excluded.
  • Associated treatments were neoadjuvant chemotherapy, adjuvant chemotherapy and postoperative radiotherapy in respectively, 4, 3 and 10 cases.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15380166.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


10. Fuchs B, Mahlum E, Halder C, Maran A, Yaszemski M, Bode B, Bolander M, Sarkar G: High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma. Gene; 2007 Sep 15;399(2):137-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma.
  • Our objective is to identify genes regulating metastasis of osteogenic sarcoma (OGS) since metastasis is the primary cause of mortality among patients with OGS.
  • We specifically searched for surface proteins over-expressed in high-grade OGS, since we hypothesize that tumor-cell specific surface markers are key to metastasis.
  • A gene encoding Tumor Endothelial Marker7 (TEM7) was selected as a candidate for further study.
  • Employing immunostaining of 92 human OGS specimens (50 high-grade and 42 low-grade) collected before chemotherapy show 97% (37 of 38) of high-grade OGS specimens with metastasis have high TEM7 staining.
  • Our results suggest TEM7 expression level closely parallels histology-based prognostication of OGS metastasis and, therefore, it is a therapeutic target.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6649-55 [11559528.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3750-9 [11325848.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):289-300 [12001990.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):89-96 [12027580.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):498-505 [12492492.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):55-63 [12509767.001]
  • [Cites] J Cell Biochem. 2003 Feb 1;88(2):408-17 [12520544.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):411-21 [12778131.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Cancer Lett. 2003 Jul 30;198(1):1-20 [12893425.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2447-56 [14635080.001]
  • [Cites] Curr Opin Oncol. 2004 Jan;16(1):44-9 [14685092.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 [14685170.001]
  • [Cites] Chin Med J (Engl). 2004 Jan;117(1):94-8 [14733782.001]
  • [Cites] Nat Med. 2004 Feb;10(2):182-6 [14704791.001]
  • [Cites] Cancer. 1971 Feb;27(2):397-402 [5100401.001]
  • [Cites] N Engl J Med. 1986 Jun 19;314(25):1600-6 [3520317.001]
  • [Cites] Pediatr Clin North Am. 1997 Aug;44(4):973-89 [9286295.001]
  • [Cites] Mol Biotechnol. 1997 Oct;8(2):135-7 [9406183.001]
  • [Cites] N Engl J Med. 1999 Jul 29;341(5):342-52 [10423470.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8507-11 [15574754.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Anal Biochem. 2000 Nov 1;286(1):91-8 [11038279.001]
  • [Cites] Gene. 2000 Nov 27;258(1-2):155-63 [11111053.001]
  • [Cites] Semin Cancer Biol. 2001 Oct;11(5):327-37 [11562175.001]
  • (PMID = 17560052.001).
  • [ISSN] 0378-1119
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR047974-01A1; United States / NIAMS NIH HHS / AR / R01 AR047974-03; United States / NIAMS NIH HHS / AR / AR47974; United States / NIAMS NIH HHS / AR / R01 AR047974-02; United States / NIAMS NIH HHS / AR / AR047974-05; United States / NIAMS NIH HHS / AR / AR047974-03; United States / NIAMS NIH HHS / AR / R01 AR047974-05; United States / NIAMS NIH HHS / AR / AR047974-04; United States / NIAMS NIH HHS / AR / AR047974-02; United States / NIAMS NIH HHS / AR / R01 AR047974; United States / NIAMS NIH HHS / AR / AR047974-01A1; United States / NIAMS NIH HHS / AR / R01 AR047974-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PLXDC1 protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, Cell Surface
  • [Other-IDs] NLM/ NIHMS29184; NLM/ PMC2066185
  •  go-up   go-down


11. Marinsek ZP, Kavalar R, Jereb B: Ewing sarcoma/PNET: 27 years of experience in Slovenia. Pediatr Hematol Oncol; 2006 Jun;23(4):355-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survival was similar whether patients received three treatment modalities or chemotherapy combined with either surgery or radiotherapy.
  • Among 18 evaluated patients, 14 had minor physical defects and 4 had severe late treatment effects (sterility in 3 and secondary osteogenic sarcoma in 1).
  • [MeSH-minor] Adolescent. Age Factors. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Humans. Infertility / etiology. Neoplasm Staging. Osteosarcoma / etiology. Recurrence. Slovenia / epidemiology. Survival Rate

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16621778.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Shiraishi J, Li Q, Appelbaum D, Pu Y, Doi K: Development of a computer-aided diagnostic scheme for detection of interval changes in successive whole-body bone scans. Med Phys; 2007 Jan;34(1):25-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a computer-aided diagnostic scheme for detection of interval changes in successive whole-body bone scans.
  • It is a well-established imaging modality for the diagnosis of osseous metastasis and for monitoring osseous tumor response to chemotherapy and radiation therapy.
  • Although the sensitivity of bone scan examinations for detection of bone abnormalities has been considered to be relatively high, it is time consuming to identify multiple lesions such as bone metastases of prostate and breast cancers.
  • Therefore, we developed a new computer-aided diagnostic (CAD) scheme for the detection of interval changes in successive whole-body bone scans by use of a temporal subtraction image which was obtained with a nonlinear image-warping technique.
  • Our computerized scheme consisted of seven steps, i.e., initial image density normalization on each image, image matching for the paired images, temporal subtraction by use of the nonlinear image-warping technique, initial detection of interval changes by use of temporal-subtraction images, image feature extraction of candidates of interval changes, rule-based tests by use of 16 image features for removing some false positives, and display of the computer output for identified interval changes.
  • The overall sensitivity in the detection of interval changes, including both hot and cold lesions evaluated by use of the resubstitution and the leave-one-case-out methods, were 95.3%, with 5.97 false positives per view, and 83.2% with 6.02, respectively.
  • Furthermore, the CAD scheme for the detection of interval changes by use of temporal subtraction images would be useful in assisting radiologists' interpretation on successive bone scan images.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278486.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62625; United States / NCI NIH HHS / CA / CA98119
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


13. Yamate J, Kotera T, Kuwamura M, Kotani T: Potential osteogenic differentiation of cisplatin-resistant rat malignant fibrous histiocytoma-derived cell lines. Exp Toxicol Pathol; 2007 Apr;58(5):299-309
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential osteogenic differentiation of cisplatin-resistant rat malignant fibrous histiocytoma-derived cell lines.
  • Histological modulations in tumor cells treated with anti-cancer drugs have been reported.
  • MT-10 developed tumors of a storiform pattern, while MT-10R and MT-PR tumors comprise round or polygonal cells arranged in a compact sheet.
  • Cisplatin-resistant MFH cells had potential to differentiate into osteogenic tissues by producing osteogenic factors, suggesting that MFH histology may be altered under anti-cancer drug treatments.
  • Recently, cancer differentiation-based therapy, that could be induced by anti-cancer drugs, has been implied.
  • MT-10R and MT-PR become useful experimental systems for studies on cellular differentiation provoked by anti-cancer drugs.
  • [MeSH-major] Bone Morphogenetic Proteins / biosynthesis. Cell Differentiation / drug effects. Cisplatin / pharmacology. Drug Resistance, Neoplasm / drug effects. Histiocytoma, Malignant Fibrous / pathology. Osteoblasts / pathology
  • [MeSH-minor] Animals. Bone Morphogenetic Protein 1. Bone Morphogenetic Protein 6. Clone Cells. Enzyme-Linked Immunosorbent Assay. Immunohistochemistry. Metalloendopeptidases / biosynthesis. Neoplasm Transplantation. Osteopontin / biosynthesis. RNA, Messenger / biosynthesis. Rats. Rats, Inbred F344. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267196.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bmp6 protein, rat; 0 / Bone Morphogenetic Protein 6; 0 / Bone Morphogenetic Proteins; 0 / RNA, Messenger; 106441-73-0 / Osteopontin; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.19 / Bmp1 protein, rat; EC 3.4.24.19 / Bone Morphogenetic Protein 1; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Chao C, Goldberg M: Surgical treatment of metastatic pulmonary soft-tissue sarcoma. Oncology (Williston Park); 2000 Jun;14(6):835-41; discussion 842-4, 847
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of metastatic pulmonary soft-tissue sarcoma.
  • The lung is the most frequent site of metastasis from soft-tissue sarcomas.
  • Due to the relative resistance of sarcoma to either chemotherapy or radiotherapy, compared to other solid tumors, surgical management of pulmonary metastases has been a pivotal therapy in this disease.
  • We review the current literature on the use of pulmonary metastasectomy in patients with soft-tissue sarcoma, as well as survival data after such treatment.
  • Osteogenic sarcoma is not included in this discussion.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / surgery. Sarcoma / secondary. Sarcoma / surgery. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor. Humans. Neoplasm Recurrence, Local. Patient Selection. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10887634.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 28
  •  go-up   go-down


15. Klepacka T, Woźniak W, Liebhart M, Michalak E, Kuczabski M, Rychłowska M: [Local recurrences after salvage operations in the therapy of osteogenic sarcoma cases - an analysis of adverse effects based on studied cases]. Med Wieku Rozwoj; 2000 Apr-Jun;4(2 Suppl 2):67-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local recurrences after salvage operations in the therapy of osteogenic sarcoma cases - an analysis of adverse effects based on studied cases].
  • Therapeutic approach in osteogenic sarcoma until 1982 was connected mainly with surgery.
  • Introduction of chemotherapy to the therapeutic protocols of osteogenic sarcoma improved the 5 years survival of patients with osteogenic sarcoma from 20% to 60-70%.
  • The approach to surgical treatment was also changed.
  • The principle of this treatment is usually to perform an operation to spare the limb with an intraoperative frozen section examination of bone marrow.
  • In our Institute during the last 14 years about 300 cases were diagnosed, out of which about 200 were treated surgically, among these about 50% underwent treatment by salvage operations.
  • Five of these cases were tumours of distal metaphysis of the femur, one case of proximal metaphysis of the tibia and one case of proximal metaphysis of the humeral bone.
  • Various factors playing a role in therapeutic adversities were analysed.
  • Among these were: radical surgery, grade of differentiation of the tumour, histological subtype, soft tissue infiltration, reaction to preoperative therapy and the type of chemotherapy.
  • The conducted analysis indicates the role played by sparing surgery in adversities in therapy (3 cases).
  • Attention was also given to the distinct tendency of osteogenic sarcoma to produce vascular embolism which is a source of haematogenously spreading metastases.
  • A certain role in therapeutic adverities is played by the lack of response to preoperative chemotherapy (4/7 cases).
  • [MeSH-major] Bone Neoplasms / surgery. Neoplasm Recurrence, Local. Osteosarcoma / surgery. Salvage Therapy / adverse effects
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Child. Female. Humans. Male. Risk Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11178330.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


16. Morris CD, Gorlick R, Huvos G, Heller G, Meyers PA, Healey JH: Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop Relat Res; 2001 Jan;(382):59-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma.
  • Prognostic biologic factors that can be assessed at the time of diagnosis for patients with osteogenic sarcoma have not been identified.
  • The current study was designed to evaluate the prognostic significance of the human epidermal growth factor receptor 2 as it relates to histologic response to preoperative chemotherapy and event-free survival.
  • A retrospective immunohistochemical study was performed on material from patients who were newly diagnosed with osteogenic sarcoma who were treated according to the T12 protocol from the authors' institution between 1986 to 1993.
  • At the time of initial biopsy, 42.6% of the samples showed HER2/erbB-2 overexpression.
  • In addition, HER2/erbB-2 expression was associated with significantly less tumor necrosis after preoperative chemotherapy as determined by the Huvos grading system.
  • These data suggest that HER2/erbB-2 should be evaluated prospectively as a prognostic indicator and clinical trials using antibodies that target this receptor should be considered for the treatment of patients with osteogenic sarcoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Neoplasms / surgery. Osteosarcoma / surgery. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cohort Studies. Coloring Agents. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Male. Neoplasm Recurrence, Local / pathology. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate


17. Zunino JH, Johnston JO: Prognostic value of histologic tumor necrosis assessment in osteogenic sarcoma of bone. Am J Orthop (Belle Mead NJ); 2000 May;29(5):369-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of histologic tumor necrosis assessment in osteogenic sarcoma of bone.
  • To assess the prognostic value of tumor necrosis in osteogenic sarcoma of bone, we designed a retrospective study of 18 patients with classic osteogenic sarcoma (OGS) in which several factors were considered as the common criteria of inclusion.
  • Forty percent of patients with > or = 95% necrosis related to chemotherapy of their primary tumor experienced metastatic disease and/or tumor recurrence during their follow-up, while 50% of those with < 95% necrosis had a disease-free period of > or = 5 years.
  • Tumor necrosis related to chemotherapy in OGS does not seem to represent, as a single predictor of disease-free survival, an accurate clinical prognostic indicator.
  • [MeSH-minor] Adolescent. Adult. Apoptosis. Child. Disease-Free Survival. Female. Humans. Male. Neoplasm Recurrence, Local. Osteonecrosis / diagnosis. Predictive Value of Tests. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10868437.001).
  • [ISSN] 1078-4519
  • [Journal-full-title] American journal of orthopedics (Belle Mead, N.J.)
  • [ISO-abbreviation] Am J. Orthop.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


18. Klepacka T, Rytwinski K, Wnuk A, Michalak E, Wozniak W: [Value of comparing flow cytometry examination and histopathology in prognosing of osteogenic sarcoma - preliminary report]. Med Wieku Rozwoj; 2000 Jul-Sep;4(3):261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of comparing flow cytometry examination and histopathology in prognosing of osteogenic sarcoma - preliminary report].
  • Our preliminary report presents two cases of osteogenic sarcoma examined after initial chemotherapy.
  • In both cases histological maps with morphological effects of chemotherapy and flow cytometry of DNA content in tumour cells were made.
  • The correlations between histological grade, proliferative potential of tumours with the morphological effects of chemotherapy were confirmed in the presented cases.
  • Analysis of the two methods of estimation of osteogenic sarcoma suggests that flow cytometry may be a complementary method to histological examination and estimation of proliferating rate, especially aneuploid cell population and this information can be helpful in clinical management.
  • [MeSH-minor] Adolescent. Child. DNA, Neoplasm / analysis. Female. Flow Cytometry / methods. Histological Techniques. Humans. Male. Prognosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11093343.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


19. Lin SY, Chen WM, Wu HH, Chen WY, Chen TH: Extraosseous osteogenic sarcoma. J Chin Med Assoc; 2005 Nov;68(11):542-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraosseous osteogenic sarcoma.
  • Extraosseous osteogenic sarcoma is a very rare malignant neoplasm.
  • Out of the more than 400 cases of soft tissue sarcomas on file in our hospital, only 2 were extraosseous osteogenic sarcomas.
  • The diagnosis of high-grade osteosarcoma primarily arising in soft tissue was made from histopathologic examination.
  • Radiotherapy of 60 Gy in 30 fractions was given postoperatively.
  • The second patient, primarily diagnosed as having a soft tissue sarcoma, was treated by wide excision.
  • The final pathologic report was high-grade extraosseous osteogenic sarcoma.
  • Adjuvant chemotherapy was given postoperatively.
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323400.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


20. Lejman T, Sułko J: [Telangiectatic osteogenic sarcoma]. Chir Narzadow Ruchu Ortop Pol; 2004;69(4):245-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Telangiectatic osteogenic sarcoma].
  • In 3 children the tumor was located in the proximal epiphysis of the femur and in the remaining 3 cases in the distal epiphysis of the femur.
  • All cases were given pre-op chemotherapy (Cisplatin, Adriablastine).
  • In all cases quick growth of the tumor was noted and in all cases a pathological fracture occurred.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Fractures, Spontaneous / etiology. Humans. Male. Neoplasm Metastasis. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15587380.001).
  • [Journal-full-title] Chirurgia narzadów ruchu i ortopedia polska
  • [ISO-abbreviation] Chir Narzadow Ruchu Ortop Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


21. Luna-Ortiz K, Villavicencio-Valencia V, Carmona-Luna T, Pasche P, Mosqueda-Taylor A: Osteogenic sarcoma of the maxillary region in a Mexican mestizo population. J Craniofac Surg; 2010 Nov;21(6):1709-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteogenic sarcoma of the maxillary region in a Mexican mestizo population.
  • BACKGROUND AND OBJECTIVES: This study analyzed maxillary osteosarcoma in a mestizo population, with particular emphasis on the type of treatment and disease-free and overall survival.
  • Mean evolution time to diagnosis was 13 months, with a mean tumor size of 7 × 6 cm2.
  • Surgery was the initial treatment in 19 patients, 17 of whom received adjuvant treatment.
  • CONCLUSIONS: Osteosarcomas of the maxilla are infrequent lesions that merit early diagnosis and proper treatment because of their rapid evolution.
  • Treatment is currently based on a well-planned surgery with free surgical margins plus adjuvant radiotherapy and/or chemotherapy.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Chemotherapy, Adjuvant / statistics & numerical data. Disease-Free Survival. Follow-Up Studies. Humans. Mexico / epidemiology. Middle Aged. Neoadjuvant Therapy / statistics & numerical data. Neoplasm Recurrence, Local / epidemiology. Osteotomy / statistics & numerical data. Radiotherapy, Adjuvant / statistics & numerical data. Retrospective Studies. Sex Factors. Survival Rate. Time Factors. Treatment Outcome. Young Adult

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119405.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Wang LL: Biology of osteogenic sarcoma. Cancer J; 2005 Jul-Aug;11(4):294-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology of osteogenic sarcoma.
  • Osteosarcoma is the most common primary malignant bone tumor in children and adolescents.
  • Despite significant clinical improvements over the past several decades through the use of combination chemotherapy and surgery, patients with metastatic or recurrent disease continue to have a very poor prognosis.
  • Therefore, there is a continued need to study and understand the basic biology of osteosarcoma in order to devise more targeted and rational therapeutic strategies and ultimately to improve survival for these patients.
  • This article reviews several aspects of osteosarcoma biology where data exist to suggest that specific pathways may play a role in the pathogenesis of this tumor.
  • These areas include host genetic predispositions, tumor cytogenetics, molecular genetics (including the Rb, p53, RECQ helicase, and telomere pathways), and metastatic factors (ezrin, annexin 2, chemokine receptor 4, Fas/FasL pathways) that may contribute to both the initiation and the progression of tumor formation.
  • Understanding the mechanisms of and interactions between the various molecular pathways that play a role in osteosarcoma pathogenesis may eventually lead to a more rational strategy for devising therapies targeted specifically toward these pathways.
  • [MeSH-minor] Adolescent. Child. Humans. Neoplasm Metastasis / genetics. Neoplasm Metastasis / physiopathology. Prognosis


23. Canadian Society of Otolaryngology-Head and Neck Surgery Oncology Study Group: Osteogenic sarcoma of the mandible and maxilla: a Canadian review (1980-2000). J Otolaryngol; 2004 Jun;33(3):139-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteogenic sarcoma of the mandible and maxilla: a Canadian review (1980-2000).
  • OBJECTIVE: To determine factors that influence survival in patients with osteogenic sarcoma of the jaws.
  • STUDY DESIGN: Multicentre retrospective clinical pathologic study of 35 patients with osteogenic sarcoma of the jaws by the Canadian Society of Otolaryngology-Head and Neck Surgery Oncology Study Group.
  • METHODS: Clinical charts and pathology results were reviewed on 35 patients treated between 1980 and 2000 for osteogenic sarcoma of the maxilla or mandible.
  • The following variables were examined for the effect on survival: age, gender, tumour site, grade and subtype, margins, and method of treatment.
  • There was a trend toward better prognosis in those who received chemotherapy in addition to surgery.
  • CONCLUSION: Osteogenic sarcoma of the jaws is an aggressive disease with a high mortality rate despite a relatively low risk of distant metastases.
  • Chemotherapy, although contentious, should be considered given the data from long bone studies and the trend toward better survival in several studies, including ours.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Canada / epidemiology. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Registries. Retrospective Studies. Sex Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841989.001).
  • [ISSN] 0381-6605
  • [Journal-full-title] The Journal of otolaryngology
  • [ISO-abbreviation] J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Canada
  •  go-up   go-down


24. Hsu JS, Chou SH, Tsai KB, Chuang MT: Lingual carcinoma metastases presenting as spontaneous pneumothorax. J Formos Med Assoc; 2009 Sep;108(9):736-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He developed lung metastases and spontaneous pneumothorax 22 months later after intra-arterial infusion chemotherapy.
  • The patient recovered uneventfully and continued to receive adjuvant chemotherapy in the oncology surgery outpatient department.
  • Unfortunately, the tumors of the tongue and cervical lymph nodes progressively enlarged despite treatment.
  • In most of the previously reported cases, pulmonary metastases associated with spontaneous pneumothorax usually originate from osteogenic or soft-tissue sarcomas.
  • Despite advanced disease, surgical treatment may be feasible.

  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773213.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


25. Rousseau J, Escriou V, Perrot P, Picarda G, Charrier C, Scherman D, Heymann D, Rédini F, Trichet V: Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Ther; 2010 Jun;17(6):387-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models.
  • Osteosarcoma is the most common malignant primary bone tumor for which pertinent preclinical models are still needed to develop new therapeutic strategies.
  • To optimize the delivery of small interfering RNA to its cellular target and demonstrate their efficiency in vivo, two new osteosarcoma models expressing the firefly luciferase enzyme were developed.
  • These luciferase-expressing osteosarcomas showed conserved osteolytic and osteogenic activities in mice and were detectable by in vivo bioluminescence imaging.
  • In comparison with measurement of tumor volume, bioluminescence analysis enabled earlier tumor detection and revealed extensive cell death in response to ifosfamide treatment.
  • [MeSH-minor] Animals. Cell Line. Cell Line, Tumor. Flow Cytometry. Genetic Vectors / genetics. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Humans. Lentivirus / genetics. Luciferases, Firefly / genetics. Luciferases, Firefly / metabolism. Male. Mice. Mice, Inbred C3H. Mice, Inbred Strains. Mice, Nude. Neoplasm Transplantation. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / genetics. Neoplasms, Experimental / metabolism. Rats. Transfection. Transplantation, Heterologous. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20075983.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Luminescent Proteins; 0 / RNA, Small Interfering; 147336-22-9 / Green Fluorescent Proteins; EC 1.13.12.7 / Luciferases, Firefly
  •  go-up   go-down


26. Maeda H, Wada N, Nakamuta H, Akamine A: Human periapical granulation tissue contains osteogenic cells. Cell Tissue Res; 2004 Feb;315(2):203-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human periapical granulation tissue contains osteogenic cells.
  • Bone defects caused by periapical inflammation can be treated and improved by endodontic therapy.
  • However, the mechanism for osseous healing of periapical lesions after root canal treatment is unclear.
  • In this study we examined whether fibroblastic cells from human periapical granulation tissue could produce calcified matrix in vitro.
  • These results suggest that inflamed periapical granulation tissue contains osteogenic cells that have the potential to differentiate into mature osteoblastic or cementoblastic cells, and that such cells might contribute to osseous healing after root canal treatment.
  • [MeSH-major] Calcification, Physiologic / physiology. Fibroblasts / metabolism. Granulation Tissue / metabolism. Periapical Tissue / metabolism. Sialoglycoproteins / metabolism
  • [MeSH-minor] Aged. Alkaline Phosphatase / metabolism. Ascorbic Acid / pharmacology. Cell Differentiation / drug effects. Cell Differentiation / physiology. Cells, Cultured. Core Binding Factor Alpha 1 Subunit. Enzyme Activation / drug effects. Female. Glycerophosphates / pharmacology. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Osteocalcin / metabolism. Osteopontin. RNA, Messenger. Transcription Factors / metabolism

  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14648194.001).
  • [ISSN] 0302-766X
  • [Journal-full-title] Cell and tissue research
  • [ISO-abbreviation] Cell Tissue Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 1 Subunit; 0 / Glycerophosphates; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 0 / Transcription Factors; 104982-03-8 / Osteocalcin; 106441-73-0 / Osteopontin; EC 3.1.3.1 / Alkaline Phosphatase; PQ6CK8PD0R / Ascorbic Acid; WWH06G87W6 / beta-glycerophosphoric acid
  •  go-up   go-down


27. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science; 2002 Jul 5;297(5578):102-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pharmacological inactivation of oncogenes is being investigated as a possible therapeutic strategy for cancer.
  • One potential drawback is that cessation of such therapy may allow reactivation of the oncogene and tumor regrowth.
  • We used a conditional transgenic mouse model for MYC-induced tumorigenesis to demonstrate that brief inactivation of MYC results in the sustained regression of tumors and the differentiation of osteogenic sarcoma cells into mature osteocytes.
  • Thus, brief MYC inactivation appears to cause epigenetic changes in tumor cells that render them insensitive to MYC-induced tumorigenesis.
  • These results raise the possibility that transient inactivation of MYC may be an effective therapy for certain cancers.
  • [MeSH-minor] Animals. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Apoptosis. Cell Differentiation. Cell Division. Doxycycline / pharmacology. Gene Expression / drug effects. Mice. Mice, Transgenic. Neoplasm Transplantation. Osteocytes / cytology. Phenotype. Transgenes. Tumor Cells, Cultured


28. Picci P: Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis; 2007;2:6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma (osteogenic sarcoma).
  • Osteosarcoma is a primary malignant tumour of the skeleton characterised by the direct formation of immature bone or osteoid tissue by the tumour cells.
  • Osteosarcoma arises predominantly in the long bones and rarely in the soft tissues.
  • Plain radiographs, computed tomography, magnetic resonance imaging, angiography and dynamic bone scintigraphy are used for diagnosis, evaluation the extent of tumour involvement and decision of the type of operation and, if necessary, the type of reconstruction.
  • Today, for localised osteosarcoma at onset (80% of cases) treated in specialized bone tumour centres with pre- and postoperative chemotherapy associated with surgery, the percentage of patients cured varies between 60% and 70%.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / therapy. Osteosarcoma / diagnosis. Osteosarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Diagnosis, Differential. Female. Humans. Incidence. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Middle Aged. Neoplasm Staging. Neoplasms, Bone Tissue / diagnosis. Prognosis. Sex Distribution

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 2002 Apr;84(3):395-400 [12002500.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1126-34 [12853357.001]
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4016-27 [11118462.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(1):39-46 [11165128.001]
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):171-5 [11748477.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1601-4 [11822761.001]
  • [Cites] J Bone Joint Surg Br. 2002 Jan;84(1):88-92 [11837839.001]
  • [Cites] Clin Orthop Relat Res. 1973 Nov-Dec;(97):64-8 [4521231.001]
  • [Cites] Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1976 May-Jun;81(3 Pt 1):454-7 [1066869.001]
  • [Cites] Recent Results Cancer Res. 1976;(54):92-103 [189372.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):5-15 [1370176.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):925-30 [8164043.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1208-14 [7850721.001]
  • [Cites] Orthop Clin North Am. 1996 Jul;27(3):473-81 [8649730.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):76-84 [8996127.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):2011-8 [12743156.001]
  • (PMID = 17244349.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 20
  • [Other-IDs] NLM/ PMC1794406
  •  go-up   go-down


29. Khaldi L, Athanasiou ET, Hadjitheofilou CT: Primary mammary osteogenic sarcoma. Histol Histopathol; 2007 04;22(4):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mammary osteogenic sarcoma.
  • Microscopically the tumor was identical to grade II skeletal osteosarcoma.
  • The diagnosis of this tumor fulfills certain clinicopathological criteria.
  • Mammary osteosarcoma is usually developed in phyllodes tumors or carcinosarcomas of the breast as a result of metaplasia of the epithelial component.
  • This rare tumor of the breast is occasionally associated with prior radiation therapy or well documented trauma.
  • Mammary osteosarcoma is a biologically aggressive neoplasm with a 38% five-year survival rate.
  • Surgical resection is the most effective therapy to date.
  • Adjuvant treatment -chemotherapy or radiotherapy- has shown no clear benefit.
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Fluorescent Antibody Technique, Indirect. Humans. In Situ Hybridization, Fluorescence. Lymph Node Excision. Mastectomy


30. El Fekih L, Hassene H, Abdelghaffar H, Fenniche S, Belhabib D, Ben Miled K, Mezni F, Megdiche ML: [Rare localization of sarcoma in an adolescent: thoracic Ewing sarcoma]. Tunis Med; 2010 Apr;88(4):265-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ewing Sarcoma is considered as primitive neuro ectodermic tumor.
  • It's the most frequent osseous tumor in children and adolescent.
  • It was localised frequently at long osseous and pelvis, however, it can be arising from the rib.
  • Morphologic aspects and immunohistochimical study for the operator piece concluded at Ewing sarcoma of the children considered as primitive neuro ectodermic tumor.
  • Six cures of chemotherapy had been prescribed with well recuperation of the motor failure.
  • [MeSH-minor] Adolescent. Female. Humans. Spinal Neoplasms / secondary. Spinal Neoplasms / therapy

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446262.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


31. Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, Antonescu CR, Wright JJ, Schwartz GK: A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer; 2005 Apr 1;103(7):1431-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arm A included patients with osteogenic sarcoma, Ewing sarcoma, and rhabdomyosarcoma.
  • Arm B accrued patients with other types of soft tissue sarcomas.
  • Patients were not allowed to have received previous chemotherapy for metastatic disease.
  • CONCLUSIONS: Bortezomib has minimal activity in soft tissue sarcoma as a single agent.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Boronic Acids / therapeutic use. Proteasome Inhibitors. Pyrazines / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bortezomib. Drug Administration Schedule. Fatigue / chemically induced. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nervous System Diseases / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15739208.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM17105; United States / NCI NIH HHS / CA / P01-CA47179
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


32. Cates JM, Friedman DB, Seeley EH, Dupont WD, Schwartz HS, Holt GE, Caprioli RM, Young PP: Proteomic analysis of osteogenic sarcoma: association of tumour necrosis factor with poor prognosis. Int J Exp Pathol; 2010 Aug;91(4):335-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of osteogenic sarcoma: association of tumour necrosis factor with poor prognosis.
  • A significant proportion of patients with osteogenic sarcoma die from lung metastasis within 5 years of diagnosis.
  • Molecular signatures that predict pulmonary metastasis from primary osteogenic sarcoma and identify those patients at risk would be clinically useful as prognostic markers.
  • Protein expression profiles of two clonally related murine osteogenic sarcoma cell lines with low (K12) and high (K7M2) metastatic potential were compared using two different proteomic technologies, two-dimensional difference gel electrophoresis and cell profiling by matrix-assisted laser desorption/ionization mass spectrometry.
  • Interrogation of a molecular pathways network database suggested several additional candidate molecules that potentially predict metastatic potential of primary osteogenic sarcoma.
  • Levels of migration inhibitory factor and tumour necrosis factor were semi-quantitatively measured in human osteogenic sarcoma samples by immunohistochemistry and were correlated with clinicopathologic parameters and patient outcomes.
  • Multivariate survival analysis demonstrated that tumour necrosis factor expression in chemotherapy naïve osteogenic sarcoma is an independent prognostic factor for overall and metastasis-free survival.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2284-8 [14676807.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5442-53 [14654523.001]
  • [Cites] Proteomics. 2004 Mar;4(3):793-811 [14997500.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):314-20 [15251122.001]
  • [Cites] Oncologist. 2004;9(4):422-41 [15266096.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6528-34 [15475440.001]
  • [Cites] J Exp Med. 1988 Mar 1;167(3):1067-85 [3351434.001]
  • [Cites] Differentiation. 1988 Dec;39(3):151-60 [3243385.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9093-100 [15604278.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1050-8 [15709171.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):394-401 [15677390.001]
  • [Cites] Intern Med J. 2005 Jul;35(7):419-26 [15958113.001]
  • [Cites] Ann Biomed Eng. 2005 Sep;33(9):1270-80 [16133932.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5950-9 [16135466.001]
  • [Cites] J Am Soc Nephrol. 2005 Oct;16(10):2967-75 [16079267.001]
  • [Cites] Cancer J. 2005 Jul-Aug;11(4):294-305 [16197719.001]
  • [Cites] Orthop Clin North Am. 2006 Jan;37(1):1-7 [16311106.001]
  • [Cites] Chem Res Toxicol. 2005 Oct;18(10):1575-85 [16533022.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):745-50 [16517151.001]
  • [Cites] Oncogene. 2006 Jun 15;25(25):3501-8 [16449971.001]
  • [Cites] Int Immunopharmacol. 2006 Oct;6(10):1527-34 [16919824.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8730-9 [17142775.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):150-69 [17028091.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):585-92 [17234767.001]
  • [Cites] J Med Chem. 2007 Apr 19;50(8):1993-7 [17385848.001]
  • [Cites] Front Biosci. 2008;13:2774-83 [17981752.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Mar;134(3):281-97 [17965883.001]
  • [Cites] PLoS One. 2008;3(5):e2215 [18493321.001]
  • [Cites] Front Biosci. 2008;13:5094-107 [18508572.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1340-6 [18325912.001]
  • [Cites] Clin Orthop Relat Res. 2008 Sep;466(9):2107-13 [18563508.001]
  • [Cites] J Orthop Res. 2008 Nov;26(11):1520-5 [18473395.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D169-74 [18836194.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):338-48 [19118019.001]
  • [Cites] Curr Med Chem. 2009;16(9):1091-114 [19275614.001]
  • [Cites] Nat Rev Cancer. 2009 May;9(5):361-71 [19343034.001]
  • [Cites] J Surg Res. 2010 May 1;160(1):29-34 [19726058.001]
  • [Cites] Clin Exp Metastasis. 2003;20(7):665-74 [14669798.001]
  • [Cites] Cytokine. 2000 Apr;12(4):309-14 [10805210.001]
  • [Cites] Clin Exp Metastasis. 2000;18(3):261-71 [11315100.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;995:171-82 [12814949.001]
  • [Cites] Lancet Oncol. 2003 Sep;4(9):565-73 [12965278.001]
  • [Cites] Cell Signal. 2004 Jan;16(1):13-9 [14607271.001]
  • [Cites] Proteomics. 2003 Oct;3(10):2019-27 [14625864.001]
  • [Cites] Nat Med. 2004 Feb;10(2):182-6 [14704791.001]
  • (PMID = 20353421.001).
  • [ISSN] 1365-2613
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA068485; United States / NIGMS NIH HHS / GM / R01 GM058008; United States / NIGMS NIH HHS / GM / 5R01GM58008; United States / NCI NIH HHS / CA / P30 CA68485
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Macrophage Migration-Inhibitory Factors; 0 / Tumor Necrosis Factor-alpha; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.2.1 / Mif protein, mouse
  • [Other-IDs] NLM/ PMC2962892
  •  go-up   go-down


33. Bar-Sela G, Tzuk-Shina T, Zaaroor M, Vlodarsky Y, Tsalik M, Kuten A: Primary osteogenic sarcoma arising from the dura mater: case report. Am J Clin Oncol; 2001 Aug;24(4):418-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary osteogenic sarcoma arising from the dura mater: case report.
  • A 42-year-old woman who sought treatment for left drop foot was found to have a right frontoparietal parasagittal mass.
  • Gross total resection of the tumor was performed and pathologic analysis revealed high grade osteoblastic osteosarcoma.
  • The patient received adjuvant chemotherapy and continues to do well with no evidence of metastases or local recurrence 3 years after initial presentation.
  • [MeSH-minor] Adult. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Chemotherapy, Adjuvant. Female. Humans. Neoplasm Invasiveness

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11474278.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Bose B: Primary osteogenic sarcoma of the skull. Surg Neurol; 2002 Sep-Oct;58(3-4):234-9; discussion 239-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary osteogenic sarcoma of the skull.
  • BACKGROUND: An osteogenic sarcoma of the skull is rare, particularly as a primary tumor.
  • The incidence of primary osteogenic sarcomas of the skull is about 1 to 2% of all skull tumors.
  • A computed tomography scan revealed a large mass, 12 cm x 7 cm, involving the scalp extending from the right temporal region to the vertex.
  • The MRI showed marked vascularity and neovascularity of the tumor.
  • CONCLUSION: We review the literature of reported cases of primary osteogenic sarcomas of the skull to discuss the common clinical presentation, evaluation methods, and recommended treatment plans.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Cements. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neovascularization, Pathologic / diagnosis. Prosthesis Implantation. Tomography, X-Ray Computed

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12480227.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Cements
  •  go-up   go-down






Advertisement